- IN₹475.31bn
- IN₹673.96bn
- IN₹152.62bn
- 48
- 15
- 62
- 35
Annual balance sheet for Biocon, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 32,233 | 29,645 | 37,260 | 25,738 | 45,647 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 22,370 | 27,805 | 40,114 | 72,591 | 63,243 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 76,004 | 83,823 | 123,340 | 151,792 | 162,862 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 79,641 | 93,643 | 101,226 | 119,778 | 134,141 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 185,223 | 203,940 | 520,428 | 560,707 | 587,973 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 42,101 | 38,280 | 85,107 | 153,588 | 143,338 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 108,954 | 119,615 | 341,759 | 362,870 | 371,533 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 76,269 | 84,325 | 178,669 | 197,837 | 216,440 |
| Total Liabilities & Shareholders' Equity | 185,223 | 203,940 | 520,428 | 560,707 | 587,973 |
| Total Common Shares Outstanding |